Mar 02, 2021 / 01:30PM GMT
David Breadon Common - JPMorgan Chase & Co, Research Division - MD, Head of North American High Yield Credit Research and Senior Analyst
Good morning again, everybody. This is David Common, and I'm very happy to start off our Tuesday sessions with Teva Pharmaceuticals, returning for another conference appearance.
For this presentation, we have Eli Kalif. He's going to step us through slides. I think we're apt to use the entire 35 minutes. So I'm going to go off-camera for the slide presentation, leave it to Eli. And if you have follow-up questions, as you know, Kevin Mannix in Investor Relations is always available, as am I.
So again, thank you, Eli, for doing this with us, and over to you.
Eliyahu Sharon Kalif - Teva Pharmaceutical Industries Limited - Executive VP & CFO
Thank you, David. Welcome, everyone, to this call, and thank you for your interest in Teva. I will review some of our key business highlights and then will review as well financials.
If we can go to Slide #3, please. We are very pleased, 2020, especially
Teva Pharmaceutical Industries Ltd at JPMorgan Global High Yield & Leveraged Finance Conference (Virtual) Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers